PGEN: Precigen, Inc. Stock

by  •  • Comments Off on PGEN: Precigen, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 392.55
Enterprise Value ($M) 391.25
Book Value ($M) 66.73
Book Value / Share 0.23
Price / Book 5.88
NCAV ($M) 23.88
NCAV / Share 0.08
Price / NCAV 16.44

Profitability (mra)
Return on Invested Capital (ROIC) -1.75
Return on Assets (ROA) -0.94
Return on Equity (ROE) -1.30

Liquidity (mrq)
Quick Ratio 4.76
Current Ratio 4.76

Balance Sheet (mrq) ($M)
Current Assets 102.41
Assets 145.27
Liabilities 78.53
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 3.92
Operating Income -94.70
Net Income -126.23
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -68.17
Cash from Investing -20.71
Cash from Financing 110.58

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-12 13G/A Patient Capital Management, LLC 6.53 10.64
12-30 13D/A Kirk Randal J 39.80 0.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-04-28 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPO
2025-03-19 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTI
2024-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-05-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-05-09 239,611 775,106 30.91
2025-05-08 827,991 2,234,408 37.06
2025-05-07 344,981 936,870 36.82
2025-05-06 583,644 1,949,566 29.94
2025-05-05 236,080 617,985 38.20

(click for more detail)

Similar Companies
PCRX – Pacira BioSciences, Inc. PCVX – Vaxcyte, Inc.
PEPG – PepGen Inc. PHAT – Phathom Pharmaceuticals, Inc.
PHVS – Pharvaris N.V.


Financial data and stock pages provided by
Fintel.io